Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy DOI Creative Commons
Shuai Wang,

Yongsen Wang,

Xuan Wu

et al.

World Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 1, 2025

Non-small cell lung cancer (NSCLC) transforming to small (SCLC) is one of the mechanisms resistance tyrosine kinase inhibitors (TKIs). Cases NSCLC into SCLC have been discovered. However, we lack concentrated data on characteristics this population and transformed aid our insight biology clinical value with positive. We systematically reviewed published literatures summarized pathological characteristics, prognosis, cases. 140 patients adenocarcinoma (LUAD) were included in study, a median age 56.8 years. The time from first diagnosis LUAD (ttSCLC) was 20.0 months. overall survival (mOS) after 11.0 months (95% CI, 7.41 14.59 months). In univariate analysis, ever smoking (either former or current) promising predictor shorter ttSCLC (HR, 1.73; 95% 1.14 2.62; P = 0.010). TKIs therapy administered as second line beyond treatment related significant delay onset compared first-line 0.62; 0.40 0.96; 0.031). progression-free (mPFS) platinum plus etoposide conversion 3.0 Female appeared be worse outcomes transformation SCLC. Transformed exhibited poor response primary classic chemotherapy immunotherapy. It carries prognosis. Exploring novel therapeutic strategies for imperative.

Language: Английский

Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy DOI Creative Commons
Shuai Wang,

Yongsen Wang,

Xuan Wu

et al.

World Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 1, 2025

Non-small cell lung cancer (NSCLC) transforming to small (SCLC) is one of the mechanisms resistance tyrosine kinase inhibitors (TKIs). Cases NSCLC into SCLC have been discovered. However, we lack concentrated data on characteristics this population and transformed aid our insight biology clinical value with positive. We systematically reviewed published literatures summarized pathological characteristics, prognosis, cases. 140 patients adenocarcinoma (LUAD) were included in study, a median age 56.8 years. The time from first diagnosis LUAD (ttSCLC) was 20.0 months. overall survival (mOS) after 11.0 months (95% CI, 7.41 14.59 months). In univariate analysis, ever smoking (either former or current) promising predictor shorter ttSCLC (HR, 1.73; 95% 1.14 2.62; P = 0.010). TKIs therapy administered as second line beyond treatment related significant delay onset compared first-line 0.62; 0.40 0.96; 0.031). progression-free (mPFS) platinum plus etoposide conversion 3.0 Female appeared be worse outcomes transformation SCLC. Transformed exhibited poor response primary classic chemotherapy immunotherapy. It carries prognosis. Exploring novel therapeutic strategies for imperative.

Language: Английский

Citations

1